Skip to main content

Table 1 Baseline Clinical and Laboratory characteristics of patients with baseline TG ≥200 mg/dl by original study allocation

From: Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial

  Bezafibrate group (n = 234) Placebo group (n = 224) P value
Clinical characteristics
 Age, years 58 ± 7 58 ± 7 0.62
 Male 210 (90) 199 (89) 0.75
 Hypertension 78 (33) 80 (36) 0.61
 DM 28 (12) 21 (9) 0.37
 BMI, kg/m2 28 ± 4 28 ± 3 0.81
 NYHA functional class ≥2 71 (30) 53 (25) 0.41
 AP class ≥2 72 (30) 53 (23) 0.40
 Prior MI 173 (74) 171 (76) 0.60
 COPD 4 (2) 8 (4) 0.22
Medical therapy
 Anti-platelets 157 (67) 155 (69) 0.63
 Beta-blockers 116 (49) 94 (42) 0.10
 Nitrates 114 (51) 127 (54) 0.47
 Ca2+-blockers 107 (46) 116 (52) 0.11
 ACE inhibitors 30 (13) 27 (12) 0.80
 Diuretics 27 (11) 36 (16) 0.16
 Non-study LLD 136 (58) 122 (54) 0.40
Laboratory values
 Glucose 104 ± 18 103 ± 19 0.76
 Total cholesterol 215 ± 18 216 ± 18 0.46
 HDL-C 31 ± 5 32 ± 5 0.14
 LDL-C 138 ± 17 140 ± 17 0.74
 Triglycerides 235 ± 25 235 ± 29 0.94
 Fibrinogen 361 ± 74 355 ± 75 0.37
  1. Values are presented as n (%) or mean ± SD
  2. AP angina pectoris, ACE angiotensin-converting enzyme, BMI body mass index, COPD chronic obstructive pulmonary disease, DM diabetes mellitus, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LLD lipid-lowering drug, MI myocardial infarction, NYHA New York Heart Association